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The Effect of Platelet-Derived Growth
Factor on the Cellular Response of the
Periodontium: An Autoradiographic
Study on Dogs
Horn-Lay Wang,* Thomas D. Pappert/ Walter A. Castelli,* Daniel J. Chiego Jr.,§
Yu Shyr,11 and Billy A. Smith, *
Platelet-derived growth factor (PDGF) is a Polypeptide growth factor considered
to have a role in the proliferation and migration of fibroblasts at a wound healing site.
The aim of this investigation was to determine if PDGF, when applied to root surfaces,
would stimulate the proliferation of fibroblasts and further enhance regeneration. Six
mongrel dogs with healthy periodontia were selected for this study. Using a closed wound
surgical model, standardized 4x4 mm fenestration defects were created into dentin on
the mid-facial of the mesial and distal roots of 4 mandibular posterior teeth in each
quadrant. Each defect received either: 1) saline solution (C); 2) expanded polytetrafluo-
roethylene (ePTFE) membrane; 3) PDGF; or 4) ePTFE + PDGF. 3H-thymidine was
administered 1 hour prior to animal sacrifice at 1, 3, and 7 days postsurgery. Each time
period included 2 dogs with each dog undergoing the four different treatments. Slides
were prepared for autoradiography. 3H-thymidine-labeled cells were counted and results
were statistically analyzed using the Bonferroni (Dunn) t test on the SAS program. Results
indicated PDGF enhanced fibroblast proliferation when compared to the groups without
PDGF. Significant differences (P < 0.05) were noted at day 1 and 7 when PDGF and
PDGF + GT were compared to C and GT groups. No significant differences were
observed in labeled fibroblasts between the C and GT groups at any time period. These
findings suggest that PDGF enhances fibroblast proliferation in early periodontal wound
healing, whether used alone or in combination with the ePTFE membrane. / Periodontol
1994;65:429^f36.
Key Words: Fibroblasts; membranes, barrier; growth factors, platelet-derived; polyte-
trafluoroethylene/therapeutic use.
The treatment of periodontal disease by traditional methods
results in wound healing by the formation of a long junc-
tional epithelium.1"3 The ultimate goal of periodontal ther-
apy is to regenerate the periodontal supporting tissues lost
to the inflammatory disease process. There has been a major
effort to achieve this goal by using either resorbable and
nonresorbable physical barriers to impede epithelial migra-
tion or to treat diseased root surfaces with various agents
(root conditioning solutions or growth factors).46 These
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mechanical barriers work by creating a space beneath the
surgical flap which would allow the periodontal ligament
and/or bone cells to proliferate, while at the same time
blocking cells from the gingival tissues and epithelium from
gaining access to the exposed root. Recent investigations
focusing on regeneration of the periodontium have at-
tempted to define factors involved in the formation of a
new connective tissue attachment to periodontally-diseased
or denuded root surfaces.7 8 After cell adhesion to substrate,
one of the biological events involved in tissue regeneration
is specific cell-directed migration, or Chemotaxis, which is
an essential feature of many biological processes in both
health and disease.7
Several growth factors have been shown to possess
chemoattractant activity including platelet-derived growth
factor (PDGF), nerve growth factor, epidermal growth fac-
tor, and transforming growth factors- and ß.910 PDGF, a
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principal source of mitogens present in whole blood serum,
was discovered in 1974 when it was shown to be released
from platelets and was responsible for the growth of many
cells in culture that are serum-dependent 11-12 PDGF is a
highly cationic, dimeric protein (pi = 9.8), with molecular
masses ranging from 28,000 to 35,000 Da.1314 There are
two different PDGF Polypeptides: PDGF-A and PDGF-B
that are 56% homologous and encoded by different
genes.1517 The PDGF-A and PDGF-B genes are located on
chromosomes 7 and 22, respectively, and are independently
regulated.17 PDGF isolated from human platelets consists
of homodimers (AA or BB) or heterodimers (AB) of the
two PDGF gene products, with the heterodimer predomi-
nating.18 Recent evidence indicates that the PDGF-AB het-
erodimer and the PDGF-BB homodimer have equivalent
activity and are equally potent in stimulating DNA synthesis
in human fibroblasts.19-20
Studies reporting the use of growth factors in vivo for
periodontal regeneration have recently begun to enter the
scientific literature. Lynch and coworkers have published
several articles on the use of a combination of PDGF and
IGF-1 (insulin-like growth factor-1) in beagle dogs.4,6 A
pilot study was performed in 19894 which examined the
application of an aqueous gel of PDGF and IGF-1 on the
periodontitis-affected root surfaces of 3 dogs following open
flap debridement. Sections of the experimental sites and
controls were examined histologically 2 weeks after treat-
ment. The control specimens revealed a long junctional
epithelial attachment with no new bone formation. In con-
trast, the growth factor-treated sites exhibited significant
amounts of new bone and cementum formation. A nearly
continuous layer of osteoblasts lined the newly formed bone,
and there was a dense cellular "front" at the coronal extent
of the new bone.
Lynch's group later reported the short-term effects of
application of a combination of PDGF and IGF-1 on peri-
odontal wound healing.5 This study compared the growth
factor-containing gel to controls in 13 beagle dogs. The
results showed a statistically significant 5- to 10-fold in-
crease in new bone and cementum in PDGF-B/IGF-l-treated
sites at 2 and 5 weeks following surgery compared to con-
trols. The authors cautioned, however, that additional stud-
ies were necessary to evaluate the proper combinations, the
optimum dose, and number of doses to be used. The exact
mechanism(s) by which PDGF/IGF-1 acts to enhance peri-
odontal regeneration remains to be fully elucidated. Recent
studies by Matsuda et al.21 and Oates et al.22 indicated that
PDGFs are potent mitogenic agents for human PDL cells
in vitro. The American Academy of Periodontology's po-
sition paper23 on growth factors summarizes that these Poly-
peptide growth factors possess greater ability to control cell
growth and differentiation than any other class of molecules
currently used in dentistry. Their clinical applicability to
periodontics awaits their large-scale production, purifica-
tion, and formulation into delivery systems which control
and maximize their actions. If these obstacles can be over-
come, growth factors hold great promise for providing the
periodontist with a mechanism for stimulating true peri-
odontal regeneration. Therefore, the purpose of this inves-
tigation was to study the effect of platelet-derived growth
factor on the pattern of proliferation and migration of fi-
broblasts with and without barrier membranes.
MATERIALS AND METHODS
Animal Selection
Six adult mongrel dogs (mean weight 13 kg) with clinically
healthy periodontia and complete dentitions were selected
for this study. The research protocol was approved by The
University of Michigan Use and Care of Animal Commit-
tee. Two weeks prior to surgery each dog was sedated with
2.5% thiamylal sodium 15 to 20 mg/kg of body weight.
Initial prophylaxis consisted of hand scaling, root planing,
and tooth polishing. Subsequently, oral hygiene was main-
tained by daily brushing with 0.12% Chlorhexidine diglu-
conate solution 5 times per week. Photographs and x-rays
were taken to document the oral health and condition of the
dental supporting tissues before and after surgery. Four bi-
rooted teeth in both quadrants of the mandibular arch were
used; they included the second (P2), third (P3), and fourth
premolare (P4), and first molars (Ml). The buccal surface
of each root was used as a treatment site. This provided 16
treatment sites per dog. Two dogs were used for each time
period (1, 3, and 7 days). The sites were randomly assigned
to one of four treatment modalities: 1) sterile water (C); 2)
expanded polytetrafluoroethylene (ePTFE) membrane alone;
3) PDGF (PDGF); or 4) PDGF plus ePTFE (ePTFE +
PDGF). Eight roots (n = 8) were evaluated for each dif-
ferent treatment at different time periods. The PDGF-BB
homodimer used in this study was obtained from human
platelets and procured from a commercial firm1 (10 µg/
vial). The PDGF-BB homodimer solution was prepared at
the time of surgery by adding 1 ml of sterile saline to obtain
a solution with a concentration of 10 µg/ml. The ePTFE
membrane* was selected as the nonresorbable barrier
material.
Surgical Procedure
Each dog was anesthetized before surgery with pentobar-
bital sodium** (30 mg/kg of body weight) and an endotra-
cheal tube was placed in order to maintain a patent airway.
To control excessive gingival bleeding, 1.8 ml of 2% li-
docaine hydrochloriden with epinephrine 1:50,000 was in-
jected locally in each quadrant. A full-thickness mucoper-
iosteal flap was reflected on the buccal aspect of each
experimental tooth using a reverse bevel, scalloped inci-
sion. Vertical releasing incisions were placed mesial to each
cuspid and distal to each first molar, extending from the
'Collaborative Research Inc., Bedford, MA.
*Gore-Tex, W.L. Gore & Assoc., Inc., Flagstaff, AZ.
**Nembutal, Abbott Laboratories, Abbott Park, IL.
t+ Xylocaine, Astra Pharmaceutical Products Inc., Westboro, ME.
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Plane of sectioning
Figure 1. A. (left) Facial perspective of surgical site. B. (right) Profile
view of surgical defect.
free gingival margin to the mucogingival junction. Follow-
ing the reflection of the gingival flap, 4x4 mm square
areas were outlined on the surface of bone using a lead
pencil to indicate the location of the fenestrations. With a
slow speed end cutting bur and continuous saline drip, fen-
estrations were cut through the bone to expose the middle
half of the roots. The cementum was completely removed
and the dentin exposed (Figs. 1A and B). The defects were
rinsed and blotted dry with sterile cotton pellets. After these
procedures were completed, the defects were treated with
one of the following modalities: C, ePTFE, PDGF, or ePTFE
+ PDGF. In teeth treated with PDGF, the solution (10
ml) was applied to the root surface with a cotton pellet for
1 minute. For teeth which received ePTFE, the membrane?
were trimmed, adapted, and extended 2 to 3 mm beyond
the borders of the fenestrations to ensure complete coverage
of the defect regions. The flaps were repositioned and the
implant alignment was verified by lifting the flap and reex-
amining. Firm pressure was applied over the flaps for 3
minutes prior to suturing to ensure good flap adaptation.
Laboratory Procedures
Under general anesthesia with pentobarbital sodium, the
dogs were sacrificed at 1, 3, and 7 days following surgery
by exsanguination via the femoral arteries. One hour prior
to sacrifice, the animals were injected with tritiated thy-
midine (0.5 µ /gm body weight) through the cutaneous
veins of the legs. The use of tritiated thymidine allowed
for the labeling of the cells in the "S" phase of mitosis in
order to permit the autoradiographic analysis of the speci-
mens.24 Following sacrifice, the head and neck of each dog
was perfused with a 10% buffered formalin solution through
the common carotid arteries and refrigerated for 24 hours.
The mandibles were then dissected free and processed for
histologie specimens.
Histologie Techniques
The blocks were rinsed in water and placed in 5% formic
acid for décalcification. The formic acid solution was changed
Dentin
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A=coronal, B=apical, C=central defeci
Figure 1C. Enlargement of surgical defect area.
once every 3 days to allow décalcification to progress at a
fast rate. When the blocks were completely decalcified,
they were cut into halves, the cutting plane passing through
the axis of the experimental root in a buccolingual plane of
orientation. The sections (5 µ  ) were prepared for histo-
logical examination. Three sections representing the breadth
of each defect were processed for autoradiographic evalu-
ation. For autoradiography, 5-µ  sections were coated with
film,** exposed for 14 days, developed, and stained lightly
with Harris' hematoxylin and eosin.
Identification of Cell Types
Criteria used for identification of cell types were based on
location in relationship to blood vessels, cementum, and
bone, and on their cellular outlines. The following were
features used to define each cell type. Fibroblasts: stellate
cells located within the extracellular matrix of the PDL and
not associated with mineralized tissues or vascular struc-
tures. Cementoblasts: round, flattened or short columnar
cells intimately associated with the mineralized or premi-
neralized matrix within the iatrogenically induced defects.
Osteoblasts: round, flattened, or short columnar cells inti-
mately associated with osteoid of the alveolar bone proper.
Perivascular cells: cells in close proximity, but not in in-
timate contact with, vascular structures within the defect or
PDL. Endothelial cells: cells intimately associated with the
basement membrane of vascular, externally, or intima,
internally.
Quantification of the Cellular Response
The source of the cellular response refers to the area(s) of
the periodontium from which the proliferating cells needed
for the healing of the surgical defect originated. Distinct
quadrangular areas of approximately 400 x 400 µ  were
selected for determining the source and counting of active
labeled cells (Fig. 1C). Two areas were identified in that
part of the periodontal ligament and alveolar bone that were
aligned either with the apical or coronal border of the dental
defect. A third area was located in the central part of the
"Kodak NTB-2, Eastman Kodak Company, Rochester, NY.
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defect adjacent to the dentinal defect. These areas were used
primarily for determining the source and quantification of
active cells in the specimens. Cells having undergone active
proliferation were marked in the "S" phase of the mitosis
by tritiated thymidine. A cell was considered to be in active
proliferation and therefore marked if it contained a mini-
mum of three reduced silver halide grains. The calculation
of the number of cells in each area was obtained by utilizing
a 400 X 400 µ  square grid x 400. Labeled cells were
identified and placed into one of the following categories:
Fibroblasts, osteoblasts, cementoblasts, perivascular, en-
dothelial, or inflammatory cells.
Statistical Analysis
For analysis of data, analysis of variance (ANOVA) was
utilized. For testing differences between the four treat-
ments, a Bonferroni /-test was performed in each time point.
A Bonferroni r-test was also employed to test the differ-
ences between means for all time effects in each treatment
area. These statistical computations were performed on the
SAS program.§§
RESULTS
Total Labeled Non-Inflammatory Cells (Mean ±
Standard Error)
There was an increase in mean labeled cells when the four
treatments and all cell types (excluding inflammatory cells)
were totaled (Table 1) at day 7 (57.9 ± 6.44 cells) com-
pared to days 1 (21.1 ± 1.8) or 3 (15.5 ± 2.0). When all
time periods and noninflammatory cell types were totaled
both PDGF (46.8 ± 7.9) and ePTFE + PDGF (44.8 ±
4.6) showed increased cellular proliferation when compared
with either the C (15.3 ± 1.8) or ePTFE (18.9 ± 2.3)
treatments (Table 2).
Total Labeled Cells (Including Inflammatory Cells)
The inclusion of the inflammatory cells obscured the trends
previously noted for the early time periods (days 1 and 3)
due to the predominance of inflammatory cells in most slide
sections (Table 2). This was particularly evident for the C
groups (mean at day 1 = 115.31, day 3 = 48.3, day 7 =
15.4). As the mean number of inflammatory cells decreased
from day 1 to day 7 (Table 3), the trend of increased labeled
cells for the PDGF containing groups became more evident.
At day 7 both PDGF and ePTFE + PDGF treatments had
significantly (P < 0.05) more active cells than either the C
or ePTFE groups.
Table 4 portrays the pattern of cellular labeling when the
5 types of noninflammatory cells (fibroblasts, cement-
oblasts, osteoblasts, perivascular, and endothelial cells) are
viewed by time, treatment, and area. At days 1 and 3 there
was a trend for more labeling for both the PDGF and the
«SAS 6.03, SAS Institute, Cary, NC.
Table 1. Total Labeled Cells (excluding inflammatory cells) in All
Areas for All Times and Treatments (mean ± standard error)
Day Control ePTFE_PDGF ePTFE + PDGF
1 16.83±2.85 14.17±2.67 27.30± 5.58 31.84±3.93*+
3 14.73±3.67 12.60 + 3.25 14.17± 3.65 21.44 ±5.61
7 13.64 ±2.74 37.60 + 6.42 87.7 ±17.46« 73.96 ±9.54*
Table 2. Total Labeled Cells (including inflammatory cells) in All
Areas for All Times and Treatments
Day Control_ePTFE_PDGF ePTFE + PDGF
1 115.3±22.09 67.78±14.22 61.37 ±14.84 98.07±12.37
3 48.29± 12.58 82.36±21.20* 30.67± 8.66 58.69± 15.10
7 15.44±3.24 48.80± 10.46 107.1 ±20.8*§ 104.9 ±13.42*§
Table 3. Total Labeled Inflammatory Cells in All Areas for All
Times and Treatments
Day Control_ePTFE_PDGF ePTFE + PDGF
1 98.56 ±20.14 53.62 ±12.57 34.07 ±9.96 66.22 ±10.80
3 33.56 ±10.40 69.76 ±18.77 16.50 ±5.38f 37.26 ±10.02+
7 1.80±0.74 11.20±4.59 19.33±4.12 30.98± 4.68*+
Significant at  < 0.05.
"Between C and GT + PDGF.
 Between GT and GT + PDGF.
 Between GT and PDGF.
§Between C and PDGF.
ePTFE + PDGF groups although this was statistically sig-
nificant (P < 0.05) only for ePTFE + PDGF compared to
the C and ePTFE groups. By day 7 both PDGF and ePTFE
+ PDGF treatments demonstrated significantly (P < 0.05)
Table 4. Labeled Cells by Time and Area for All Treatment Groups
(Mean ± Standard Error)
Day 1 Day 3_Day 7
Control
Apical 21.82±4.66 12.73± 2.95 5.46±1.07*
Middle 68.19 ±13.46 22.69 ±6.38 5.54 ±1.53+
Coronal 25.30±6.01 12.87± 4.12 4.44±1.20+
ePTFE Treatment
Apical 13.55±2.76 20.89±6.03 11.30 ±1.86
Middle 45.10 ± 11.59 37.96±9.57 23.50±6.84
Coronal 9.13 ±1.91 23.51 ±6.24* 14.00 ±2.44
PDGF
Apical 13.37±3.03 7.88±2.00 21.12±3.06*
Middle 31.63± 10.11 13.98± 4.70 70.73±16.09*
Coronal 16.37±3.44 8.82±2.48 15.26±2.66
ePTFE + PDGF Treatment
Apical 19.29±3.02 15.08 ±3.81 18.67±1.94
Middle 53.18±9.15 29.62±8.06 70.14+10.74*
Coronal 25.60 ±2.88 14.00 ±4.10 16.14±1.73+
Significant at  < 0.05.
*Between day 1 and day 3.
 Between day 1 and day 7.
 Between day 3 and day 7.
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Figure 2. Magnified view of the ePTFE-treated site at day 7. Expanded
polytetrafluoroethylene membrane separating tissues from inside to out-
side of the defect. The newly-formed granulation tissues were evident on
the inside of the defect. ePTFE = expanded polytetrafluoroethylene mem-
brane; RBC = red blood cells; BV = blood vessels; IC = inflammatory
cells (original magnification x 100; H & E stain).
C
Figure 3. Higher magnification view of the ePTFE-treated site at day 7.
Labeled fibroblasts (Fl) and perivascular cells (PV) were demonstrated
(original magnification x 400; H & E stain).
increased labeling as compared with C while the PDGF
group had significantly (P < 0.05) more cellular labeling
than ePTFE.
Total Labeled Cells by Time, Area, and Treatment
(Table 4)
Treatment C. Labeled cells significantly decreased from
day 1 to day 7 for all three observed areas (P < 0.05).
Labeled cells were found predominantly in the middle region.
Treatment ePTFE (Figs. 2 and 3). Labeled cells were
highest in mean numbers in the middle region for all times
although not significantly. The apical area showed slightly
more activity at day 1 and less at days 3 and 7 in comparison
to the coronal area.
Treatment PDGF (Fig. 4). Cellular labeling was again
seen to be more pronouned for the middle area but in con-
trast to the previous two treatments the most activity was
noted at day 7 compared to day 1 and day 3 (P < 0.05).
Figure 4 demonstrate sections from the PDGF treatment
group which show herniation and then proliferation of the
PDL fibroblasts into the defect with cellular labeling.
Treatment ePTFE + PDGF (Fig. 5). This treatment
group had a similar pattern of cell activity compared to the
PDGF group. There was more labeling in the middle por-
tion of the defect and moderate labeling apically and cor-
onally. Statistical differences existed between the coronal
areas at days 1 to 3 and days 1 to 7 and also between the
middle regions at days 3 and 7. Figure 5 shows a typical
example of the defect area with the membrane in place. It
appears as though the PDL fibroblasts are bridging across
the defect with moderate amounts of cellular labeling present.
Labeled Cells for All Times and Treatments by Cell
Type (Table 5)
Fibroblasts. The general trend was of moderate cellular
activity at day 1, decreasing at day 3, and a dramatic in-
crease at day 7. At day 1 however, significant differences
(P < 0.05) existed between the PDGF and ePTFE groups
and between the ePTFE + PDGF and both ePTFE and C
groups. No statistically significant differences were noted
at day 3. By day 7, labeling in the PDGF group was much
greater (P < 0.05) than either C or ePTFE. The ePTFE +
PDGF treatment also was significantly (P < 0.05) more
effective at enhancing cellular activity at day 7 than the C
treatment.
Cementoblasts. Labeling was least at day 3 and greatest
at day 7 for all but the C group. Significant differences (P
< 0.05) existed only between PDGF and C at day 7.
Osteoblasts. Labeling was greatest for the PDGF group
at day 7 (similar to the cementoblasts) which was signifi-
cantly different (P < 0.05) compared to the C group.
Perivascular cells. Day 7 exhibited the highest degree
of cell activity for all but the C group. Both PDGF treatment
groups were significantly greater than the C group at day
7.
Endothelial cells. The trend of highest activity for the
PDGF and ePTFE + PDGF groups at day 7 held for this
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Figure 4. Magnified view of the PDGF-treated site at day 1. Fibroblast
proliferation with evidence of newly-formed granulation tissues (original
magnification x 250;  & E stain).
cell type. Statistical differences existed only between the
ePTFE + PDGF and C groups at day 7, however.
DISCUSSION
Periodontal wound repair is the consequence of an orga-
nized series of cellular and molecular events in the struc-
turally and functionally impaired tissue. The repair of injury
begins as soon as tissue damage occurs, and the release of
Polypeptide growth factors from injured cells and inflam-
matory cells is a critical part of this process.25 This study
was initiated to provide an understanding of the effect of
PDGF, with and without barrier membranes, on cellular
proliferation during early wound healing in the dog model.
The data obtained in this research demonstrated that the
short-term exposure of periodontal tissues to PDGF can
stimulate the proliferation of fibroblasts when compared to
control or ePTFE membrane specimens. Similar findings
were reported by Matusda et al., who showed that PDGFs
have potent and comparable mitogenic effects on PDL fi-
broblastic cells.21 Our results were also in agreement with
Oates et al., who reported that PDGF-AA and PDGF-BB
are potent mitogenic agents for human PDL cells and may
Figure 5. Lower magnified view of the PDGF + ePTFE-treated site at
day 1. Defect filled with RBCs and inflammatory cells (IC) which do not
contact the tooth surface. There is apparent "bridging" of PDL cells
(—) from the coronal to apical regions. D = dentin;  = bone, PDL =
periodontal ligament; BV = blood vessels; ePTFE
—
expanded polyte-
trafluoroethylene membranes (original magnification  40;  & E stain).
play critical roles in modulating oral fibroblast cell prolif-
eration.22 The addition of an ePTFE membrane did not en-
hance the results obtained by the use of PDGF alone. No
significant differences were observed in labeled fibroblasts
between the C and ePTFE groups at any time period. This
is in agreement with the findings of Aukhil and Iglhaut26
and Iglhaut et al.,27 which indicated that there was no dif-
ference in the healing process using membrane barriers.
They found that the premitotic labeling with or without
barriers was the same.
In this study, gingival and PDL fibroblasts were exposed
to PDGF in the PDGF group whereas only the PDL fibro-
blasts were exposed to the growth factor in the ePTFE +
PDGF group. It has been suggested that gingival fibroblasts
may not have the regenerative potential of periodontal lig-
ament fibroblasts,1-3 which play a most critical role in per-
iodontium regeneration.21 No significant differences were
noted between labeled fibroblasts for either the PDGF or
the ePTFE + PDGF groups. It is, however, difficult to
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Table 5. Total Count of Specific Labeled Cells for All Times and
Treatments (Mean ± Standard Error)
ePTFE PDGF ePTFE + PDGF
Fibroblasts
Day 1 10.3 ±1.73
Day 3 7.2 ±1.83
Day 7 9.3 ±1.90
Cementoblasts
Day 1 1.41 ±0.36




Day 3 1.82 ±0.59
Day 7 0.54 ±0.19
Perivascular Cells
Dayl 1.52 ±0.48
Day 3 2.93 ±0.70
Day 7 2.69 ±0.63
Endothelial Cells
Day 1 1.17±0.29
Day 3 1.87 ±0.65









































* Between ePTFE and PDGF
 Between C and ePTFE + PDGF
 Between C and PDGF
'Between ePTFE and ePTFE + PDGF
differentiate the origin of the fibroblasts in the PDGF group
since these cells may have come from either the gingival
or PDL compartments. Perhaps either type of fibroblast is
capable of providing progenitor cells for repopulating the
wound area.
Fibroblast proliferation increased greatly from day 1 to
day 7 in both groups treated with PDGF. According to
general wound healing principles, the number of fibroblasts
begins to increase in the wound at 2 to 4 days and, follow-
ing a "lag phase" in which there are no new proteins pro-
duced in the wound, the fibroblasts begin to synthesize
collagenous and noncollagenous connective tissue proteins
actively at about 5 days.28'29 This is in agreement with the
trend seen in this study where there was a decrease in cell
activity at day 3 and increase at day 7. The 7-day PDGF
specimens exhibited areas of cell rich connective tissue at-
tachment without inflammatory cells as well as areas show-
ing the fibrin clot in various stages of résorption. Lynch et
al. determined that the half-life of PDGF was 4.2 hours
with less than 4% of the growth factor remaining present
by 96 hours.6 They felt that, although the growth factor
was absent in the later time periods (beyond 2 weeks), it
stimulated a cascade of wound healing events that continued
on even in its absence. In our research the greatest increase
in fibroblasts labeling occurred at day 7 when most of the
PDGF had become extinct.
The proliferation of inflammatory cells decreased from
day 1 to day 7. This is in agreement with typical wound
healing where the early hours following wounding consists
of clot formation and a nonreparative inflammatory phase.28
The experimental groups (ePTFE, PDGF and ePTFE +
PDGF) exhibited fewer inflammatory cells than the control
at day 1 with a sharp decrease in inflammatory cells for all
groups by day 7. As the inflammatory cells decreased they
were replaced by noninflammatory cells. Perhaps the PDGF
was actually toxic at the early stages of healing thus inhib-
iting the early inflammatory response and clot formation.
While some investigators have found PDGF to have a lim-
iting acting time at wound sites,30 the optimal in vivo dose
is still unknown5 and excessive doses may be initially toxic.
PDGF is a cytokine which works in concert with other
inflammatory type cytokines, such as interleukin-lß. In-
flammatory cells have been shown to express growth factors
and may be essential for true regeneration to occur.31 A
sustained inflammatory response may sponsor sustained cell
recruitment via the production of one or more growth factors.
Both labeled cementoblasts and osteoblasts were found
in relatively low numbers throughout all three time periods,
with significant increases found only between the PDGF
and C groups at day 7. This is somewhat in agreement with
the studies, which have shown that PDGF enhances prolif-
eration and migration of osteoblastic cells.32 33 Wound heal-
ing following full-thickness mucoperiosteal flaps typically
results in osteoclastic activity between the fourth and tenth
days of healing34 and is thus in agreement with these ob-
servations. The control group, however, demonstrated de-
creased cementoblastic labeling from day 1 to day 7, which
is the opposite of what would be expected. Lynch and co-
workers found significantly more bone and cementum (5 to
10 times more) in sites treated with PDGF and IGF-I over
controls both at 2 and 5 weeks.6 Osteoblasts are generally
not active until 7 to 14 days into the healing process while
cementogenesis does not begin for 10 to 18 days.29 There-
fore, it is not unexpected to see little activity for these
mineralized tissue forming cells in this 7-day experiment.
Labeled perivascular and endothelial cells showed a gen-
eral decrease from day 1 to day 3 and an increase at day 7
in ePTFE, PDGF, and ePTFE + PDGF groups. Typically,
revascularization of wounds begins at about 2 days as an-
gioblasts proliferate from cut surfaces of regional capillaries
and form nonpatent buds. With time, the buds fuse with
each other to form patent capillary loops, which themselves
show evidence of additional budding.28
Future studies should include a larger sample size and a
longer observation period to ensure that the entire healing
period is evaluated. The optimal dosage of PDGF to en-
hance the early wound healing is yet to be determined.
Within the limits of this study, the following conclusions
were drawn: 1) the application of PDGF in periodontal
closed wounds enhanced the proliferation of fibroblasts; 2)
the implantation of ePTFE membranes had no effect on the
total fibroblast proliferation at the wound sites, but the ex-
clusion of the gingival connective tissue cells may have
resulted in stronger cellular activity at the periodontal lig-
ament; 3) the prevalence of inflammatory cells was greater
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in the groups treated without PDGF than the groups treated
with PDGF; and 4) discrete cellular activity was observed
among cementoblasts and osteoblasts in all experimental
groups at 7 days. Perivascular and endothelial cells were
slightly more active in specimens treated with PDGF.
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